Related Experiment Video
Updated: Dec 24, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
Wei Cao1, Xiaosheng Liu2, Tao Bai3
1Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Insights
Severe COVID-19 patients showed satisfactory recovery after receiving high-dose intravenous immunoglobulin (IVIg). Further randomized studies of IVIg are recommended for deteriorating coronavirus disease 2019 patients.
Area of Science:
- Infectious Diseases
- Immunology
Background:
- The rapid global spread of coronavirus disease 2019 (COVID-19) presents a significant public health challenge.
- Effective treatments for severe COVID-19 remain limited, necessitating exploration of novel therapeutic strategies.
Purpose of the Study:
- To evaluate the potential efficacy of high-dose intravenous immunoglobulin (IVIg) in patients with severe COVID-19.
- To report on clinical observations of COVID-19 patients treated with IVIg.
Main Methods:
- Case series reporting on three patients with severe COVID-19.
- Administration of high-dose intravenous immunoglobulin (IVIg) as a therapeutic intervention.
Main Results:
- All three patients with severe COVID-19 experienced satisfactory recovery following high-dose IVIg treatment.
- Clinical improvement was observed in the treated patient cohort.
Conclusions:
- High-dose intravenous immunoglobulin (IVIg) may be a promising treatment option for severe COVID-19.
- Randomized controlled trials are warranted to confirm the efficacy of IVIg in deteriorating COVID-19 patients.
Abstract:
The outbreak of coronavirus disease 2019 (COVID-19) has spread rapidly in China. Until now, no definite effective treatment has been identified. We reported on 3 patients with severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observations, randomized studies of high-dose IVIg should be considered in deteriorating patients infected with COVID-19.
More Related Videos
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
10:24Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Myocarditis III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Myocarditis IV: Nursing Management
Immunodeficiency Diseases
There are three main causes of immunodeficiency...